NEOADJUVANT VIDUTOLIMOD (VIDU) AND NIVOLUMAB (NIVO) RESULTS IN MPR AND IMMUNE ACTIVATION IN HIGH-RISK RESECTABLE MELANOMA (MEL): FINAL PHASE II CLINICAL TRIAL RESULTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-12-083OA
PIXATIMOD (P) IN COMBINATION WITH NIVOLUMAB (N) plus /- LOW-DOSE CYCLOPHOSPHAMIDE (CY) IN ADVANCED CANCERS: A PHASE IIA BASKET TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
GENERALIZABILITY OF PREDICTIVE VERSUS PROGNOSTIC INDICATORS FROM PUBLISHED TRANSCRIPTOMIC ASSOCIATIONS WITH TUMOR RESPONSE TO IMMUNE CHECKPOINT INHIBITIONJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
MELANOMA LYMPH NODE METASTASES ARE ASSOCIATED WITH HYPOXIA AND IMMUNOLOGIC DYSFUNCTIONJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
PRELIMINARY CLINICAL EXPERIENCE WITH XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-1014OA
PRELIMINARY SAFETY, PHARMACOKINETICS/PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-107OAAI
GENERALIZABILITY OF POTENTIAL BIOMARKERS OF RESPONSE TO CTLA-4 AND PD-1 BLOCKADE THERAPY IN CANCERJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-100PREAI
A PHASE II TRIAL OF NIVOLUMAB PLUS AXITINIB IN PATIENTS WITH ANTI-PD1 REFRACTORY ADVANCED MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-092PREAI